William Cundiff, DO
Pulmonary Disease · Elizabethtown, KYNPI 1992969604
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (56.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 66.4% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2023 at $7,633 and has fallen 93.3% since, to $508 in 2025.
Across 228 payments — averaging $48.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- Insmed, Inc.$536
- GSK$374
- AstraZeneca$303
- Boehringer Ingelheim$264
- Regeneron Healthcare Solutions, Inc.$229
- plus $2K from 30 others
What the payments were for
- Travel & lodging$1,17511%
- Food & beverage$3,64333%
- Education$6,30057%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 13 | $7,381 |
| Insmed, Inc. | 24 | $536 |
| GSK | 33 | $374 |
| AstraZeneca | 19 | $303 |
| Boehringer Ingelheim | 23 | $264 |
| Regeneron Healthcare Solutions, Inc. | 9 | $229 |
| Sunovion Pharmaceuticals Inc. | 13 | $209 |
| Grifols USA, LLC | 9 | $181 |
| Actelion Pharmaceuticals US, Inc. | 8 | $171 |
| Astellas Pharma US Inc | 6 | $154 |
| Sanofi | 6 | $153 |
| Genentech USA, Inc. | 9 | $144 |
| Pulmonx Corporation | 3 | $107 |
| United Therapeutics Corporation | 6 | $99 |
| Mylan Specialty L.p. | 6 | $85 |
| Merck | 4 | $85 |
| CSL Behring | 4 | $62 |
| Bayer | 3 | $52 |
| Amgen | 3 | $52 |
| Mayne Pharma Commercial LLC | 3 | $51 |
| Philips North America LLC | 3 | $49 |
| Shire North American Group Inc | 2 | $38 |
| Galvanize Therapeutics, Inc | 1 | $36 |
| Baxter Healthcare | 2 | $35 |
| Tactile Systems Technology Inc | 2 | $33 |
| Boston Scientific | 1 | $33 |
| Viatris Specialty LLC | 2 | $32 |
| Pfizer | 2 | $28 |
| AbbVie | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Novartis | 1 | $20 |
| Siemens Medical Solutions USA, Inc. | 1 | $19 |
| Chiesi USA, Inc. | 1 | $17 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$4,242
- ION$3,000
How this compares
$11,119 in reported general payments places this provider in the 75th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 14 | $349,879 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 120 | $92,190 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 77 | $62,742 |
| Spiriva RespimatTiotropium Bromide | 105 | $61,822 |
| Tadalafil | 25 | $56,730 |
| Ambrisentan | 20 | $56,651 |
| NucalaMepolizumab | 14 | $51,612 |
| Dupixent SyringeDupilumab | 13 | $48,589 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 28 | $17,213 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $14,872 |
| SymbicortBudesonide/Formoterol Fumarate | 35 | $10,426 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $9,136 |
| Roflumilast | 93 | $7,293 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 35 | $6,273 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 246 | $6,213 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi | $171 | $349,87914 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $374 | $171,546187 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $264 | $79,035133 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $303 | $73,168112 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $13 | $5,99223 claims |
| MerckDulera | $85 | $4,16012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Elizabethtown
- Aaron MulhallElizabethtown$14K
- Navin KainiElizabethtown$11K
- John McConnellLouisville$864K
- Erica GregonisRichmond$390K
- Firas KouraGeorgetown$350K
- Harold HallerLouisville$340K
- Steven KoenigMorehead$242K
- Samantha BaahLouisville$226K
- Sandra SchuldheiszSomerset$225K
- Karim El-KershLouisville$180K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.